ANIK vs INFU
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIK is a StrongBuy and INFU is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INFU’s FA Score shows that 1 FA rating(s) are green while.
- INFU’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIK’s TA Score shows that 6 TA indicator(s) are bullish while INFU’s TA Score has 4 bullish TA indicator(s).
- ANIK’s TA Score: 6 bullish, 3 bearish.
- INFU’s TA Score: 4 bullish, 4 bearish.
Price Growth
INFU (@Medical Specialties) experienced а -2.33% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.78%. For the same industry, the average monthly price growth was +1.31%, and the average quarterly price growth was -2.62%.
Reported Earning Dates
INFU is expected to report earnings on Nov 13, 2024.
Industries' Descriptions
@Medical Specialties (+1.78% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ANIK | INFU | ANIK / INFU | |
| Capitalization | 382M | 187M | 204% |
| EBITDA | -11.23M | 16.2M | -69% |
| Gain YTD | 12.401 | -40.228 | -31% |
| P/E Ratio | 72.99 | 195.13 | 37% |
| Revenue | 167M | 123M | 136% |
| Total Cash | 72.9M | 161K | 45,280% |
| Total Debt | 29M | 36.3M | 80% |
ANIK | INFU | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 89 | |
SMR RATING 1..100 | 96 | 89 | |
PRICE GROWTH RATING 1..100 | 51 | 77 | |
P/E GROWTH RATING 1..100 | 79 | 8 | |
SEASONALITY SCORE 1..100 | 95 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANIK's Valuation (89) in the Pharmaceuticals Other industry is in the same range as INFU (94) in the Medical Specialties industry. This means that ANIK’s stock grew similarly to INFU’s over the last 12 months.
INFU's Profit vs Risk Rating (89) in the Medical Specialties industry is in the same range as ANIK (100) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.
INFU's SMR Rating (89) in the Medical Specialties industry is in the same range as ANIK (96) in the Pharmaceuticals Other industry. This means that INFU’s stock grew similarly to ANIK’s over the last 12 months.
ANIK's Price Growth Rating (51) in the Pharmaceuticals Other industry is in the same range as INFU (77) in the Medical Specialties industry. This means that ANIK’s stock grew similarly to INFU’s over the last 12 months.
INFU's P/E Growth Rating (8) in the Medical Specialties industry is significantly better than the same rating for ANIK (79) in the Pharmaceuticals Other industry. This means that INFU’s stock grew significantly faster than ANIK’s over the last 12 months.
| ANIK | INFU | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 75% | N/A |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 61% |
| TrendWeek ODDS (%) | 2 days ago 75% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 79% |
| Advances ODDS (%) | 2 days ago 69% | 7 days ago 75% |
| Declines ODDS (%) | 11 days ago 71% | 2 days ago 76% |
| BollingerBands ODDS (%) | 2 days ago 56% | 2 days ago 77% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 74% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PMSSX | 24.19 | 0.01 | +0.04% |
| Principal MidCap S&P 400 Index R1 | |||
| PPQJX | 7.70 | -0.01 | -0.13% |
| Principal MidCap Growth III J | |||
| OSMYX | 44.51 | -0.15 | -0.34% |
| Invesco International Small-Mid Com Y | |||
| RALOX | 10.54 | -0.04 | -0.38% |
| Lazard Real Assets Open | |||
| HAIGX | 16.85 | -0.07 | -0.41% |
| Harbor International Growth Instl | |||
ANIK and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIK has been loosely correlated with RVTY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIK jumps, then RVTY could also see price increases.
| Ticker / NAME | Correlation To ANIK | 1D Price Change % | ||
|---|---|---|---|---|
| ANIK | 100% | +1.07% | ||
| RVTY - ANIK | 39% Loosely correlated | +1.53% | ||
| AVNS - ANIK | 35% Loosely correlated | +0.25% | ||
| ACRS - ANIK | 34% Loosely correlated | +1.71% | ||
| FLGT - ANIK | 32% Poorly correlated | +0.68% | ||
| INFU - ANIK | 32% Poorly correlated | -1.87% | ||
More | ||||
INFU and
Correlation & Price change
A.I.dvisor indicates that over the last year, INFU has been loosely correlated with XRAY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if INFU jumps, then XRAY could also see price increases.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | -1.87% | ||
| XRAY - INFU | 37% Loosely correlated | +0.07% | ||
| SMTI - INFU | 36% Loosely correlated | -4.72% | ||
| HBIO - INFU | 34% Loosely correlated | -5.10% | ||
| ANIK - INFU | 33% Loosely correlated | +1.07% | ||
| VREX - INFU | 33% Poorly correlated | -0.72% | ||
More | ||||